KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 12, 2024
-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline results expected in 2Q 2025 --
-- Initiated five clinical trial sites for the CHASE trial in Argentina; additional sites in Latin America in process, subject to regulatory clearance --
Read more at globenewswire.com
